Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in gaucher disease in a non-jewish, caucasian cohort of gaucher disease patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Rolfs, Arndt ^a   Giese, Anne Katrin ^a   Grittner, Ulrike ^b   Mascher, Daniel ^c   Elstein, Deborah ^d   Zimran, Ari ^d   Böttcher, Tobias ^a   Lukas, Jan ^a   Hübner, Rayk ^a   Gölnitz, Uta ^e   Röhle, Anja ^e   Dudesek, Ales ^a   Meyer, Wolfgang ^f   Wittstock, Matthias ^a   Mascher, Hermann ^c  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Pharm Analyt Labor GmbH   (Austria)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e CENTOGENE AG   (Germany)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GAUCHER DISEASE; HUMANS; MALE; MIDDLE AGED; PSYCHOSINE; YOUNG ADULT;

EID: 84894280298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079732     Document Type: Article

References (36)

1. Wang RY, Bodamer OA, Watson MS, Wilcox WR (2011) ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 13: 457-84.
2. Wittmann J, Karg E, Turi S, Legnini E, Wittmann G, et al. (2012) Newborn screening for lysosomal storage disorders in Hungary. JIMD Reports 6: 117-25.
3. Nakamura K, Hattori K, Endo F (2011) Newborn screening for lysosomal storage disorders. Am J Med Genet C Semin Med Genet 157: 63-71.
4. Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, et al. (2011) Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis 34: 605-19.
5. Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM (2009) Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships. Expert Opin Pharmacother 10: 2641-52.
6. Pastores GM (2010) Neuropathic Gaucher disease. Wien Med Wochenschr 160: 605-8.
7. Aviner S, Garty BZ, Rachmel A, Baris HN, Sidransky E, et al. (2009) Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare. Blood Cells Mol Dis 43: 294-7.
8. Zimran A (2011) How I treat Gaucher disease. Blood 118: 1463-71.
9. Bodamer OA, Hung C (2010) Laboratory and genetic evaluation of Gaucher disease. Wien Med Wochenschr 160: 600-4.
10. Vedder AC, Cox-Brinkman J, Hollak CE, Linthorst GE, Groener JE, et al. (2006) Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 89: 239-44. (Pubitemid 44442987)
11. Orchard PJ, Lund T, Miller W, Rothman SM, Raymond G, et al. (2011) Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy. J Neuroinflammation 8: 144.
12. Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93: 1288-92.
13. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, et al. (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273: 25680-5.
14. Chang KL, Hwu WL, Yeh HY, Lee NC, Chien YH (2010) CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency. Blood Cells Mol Dis 44: 38-40.
15. Maire I, Guffon N, Froissart R (2007) Current development and usefulness of biomarkers for Gaucher disease follow up. Rev Med Interne 28: S187-92.
16. Schutyser E, Richmond A, Van Damme J (2005) Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 78: 14-26. (Pubitemid 40979939)
17. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, et al. (2002) Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 277: 24584-93. (Pubitemid 34951986)
18. Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, et al. (2003) PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 163: 2065-75. (Pubitemid 37310036)
19. Groener JE, Poorthuis BJ, Kuiper S, Hollak CE, Aerts JM (2008) Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta 1781: 72-8.
20. Groener JE, Poorthuis BJ, Kuiper S, Helmond MT, Hollak CE, et al. (2007) HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin Chem 53: 742-7. (Pubitemid 46580247)
21. Nilsson O, Svennerholm L (1982) Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 39: 709-18. (Pubitemid 12034962)
22. Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, et al. (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118: e118-27.
23. van Dussen L, Lips P, Everts VE, Bravenboer N, Jansen ID, et al. (2011) Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J Clin Endocrinol Metab 96: 2194-205.
24. Rosengren B, Fredman P, Månsson JE, Svennerholm L (1989) Lysosulfatide (galactosylsphingosine-3-O-sulfate) from metachromatic leukodystrophy and normal human brain. J Neurochem 52: 1035-41. (Pubitemid 19085923)
25. Lloyd-Evans E, Pelled D, Riebeling C, Futerman AH (2003) Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms. Biochem J 375: 561-5. (Pubitemid 37433504)
26. Atsumi S, Nosaka C, Iinuma H, Umezawa K (1993) Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. Arch Biochem Biophys 304: 302-4. (Pubitemid 23214185)
27. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, et al. (2010) Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 19: 1088-97.
28. Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, et al. (2010) How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta 411: 1906-14.
29. Mao XY, Burgunder JM, Zhang ZJ, An XK, Zhang JH, et al. (2010) Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China. Neurosci Lett 469: 256-9.
30. Taketomi T, Hara A, Uemura K, Sugiyama E (1996) Rapid method of preparation of lysoglycosphingolipids and their confirmation by delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J Biochem 120: 573-9. (Pubitemid 26331648)
31. Kurt I, Abasli D, Cihan M, Serdar MA, Olgun A, et al. (2007) Chitotriosidase levels in healthy elderly subjects. Ann N Y Acad Sci 1100: 185-8. (Pubitemid 47092651)
32. Seeman PJ, Finckh U, Höppner J, Lakner V, Liebisch I, et al. (1996) Two new missense mutations in a non-Jewish Caucasian family with type 3 Gaucher disease. Neurology 46: 1102-7. (Pubitemid 26134660)
33. Finckh U, Seeman P, von Widdern OC, Rolfs A (1998) Simple PCR amplification of the entire glucocerebrosidase gene (GBA) coding region for diagnostic sequence analysis. DNA Seq 8: 349-56. (Pubitemid 29170767)
34. Metz C.E (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283-98.
35. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-77. (Pubitemid 23118304)
36. Delong ER, Delong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-45.